CD19 and neoplasm: The potential clinical benefit of this cellular therapeutic approach is supported by a recent clinical trial that utilized partially HLA matched or HLA unmatched allogeneic UCB to generate anti-CD19 CAR NK cells along with IL-15 to produce significant anti-tumor activity against CD19-positive lymphoid malignancies13.